
3 natural food dyes approved by FDA
Sign up for CNN's Eat, But Better: Mediterranean Style. Our eight-part guide shows you a delicious expert-backed eating lifestyle that will boost your health for life.
The US Food and Drug Administration has approved three new color additives from natural sources 'that will expand the palette of available colors from natural sources for manufacturers to safely use in food,' the agency said in a news release.
The three dyes are Galdieria extract blue, butterfly pea flower extract and calcium phosphate.
US Department of Health and Human Services Secretary Robert F. Kennedy Jr. has made phasing out petroleum-based dyes in the nation's food supply one of the priorities in his broader initiative to 'Make America Healthy Again.'
Artificial food dyes are facing new restrictions or bans at both the federal level and in more than half the states. In April, FDA Commissioner Dr. Marty Makary announced the agency would work with the industry to remove and replace the dyes, though the FDA largely hasn't yet made this a requirement for industry.
'For too long, our food system has relied on synthetic, petroleum-based dyes that offer no nutritional value and pose unnecessary health risks,' Kennedy said in a news release. 'We're removing these dyes and approving safe, natural alternatives — to protect families and support healthier choices.'
Galdieria extract blue derives from Galdieria sulphuraria, a type of red algae that carries a water-soluble blue pigment known as C-Phycocyanin and is found in acidic volcanic hot springs and calderas, according to the FDA and Fermentalg, a French chemical company using micro-algae for colorants, foods and supplements.
Fermentalg sought approval for the additive for foods and beverages via a petition it submitted to the FDA in 2021 and has patented a Galdieria sulphuraria extract under the name Everzure.
Galdieria sulphuraria's natural ability to reside in acidic environments lends to its stability in food and beverages, which is something food and beverage manufacturers have been concerned about in the shift to natural alternatives to highly stable artificial dyes.
Butterfly pea extract is a blue color from which manufacturers can create a range of shades including bright blues, intense purples and natural greens, according to the FDA. It's produced from the water extraction of the dried flower petals of the butterfly pea plant, and is already approved for some uses, including sports drinks, fruit drinks, fruit and vegetable juices, alcoholic beverages, candy and ice creams.
Its use is now expanded to also include ready-to-eat cereals, crackers, snack mixes, hard pretzels, plain potato chips, plain corn chips, tortilla chips and multigrain chips, the FDA said. The petition that raised this extract for consideration was submitted in February 2024 by the St. Louis-based Sensient Colors, one of the largest global dye-makers.
Calcium phosphate, a mineral compound containing both calcium and phosphorus, provides a white color newly approved for use in ready-to-eat chicken products, white candy melts, doughnut sugar and sugar for coated candies, according to the FDA, whose decision approves a 2023 petition filed by New Jersey-based Innophos Inc., a mineral solutions company.
'The FDA determines whether an additive is safe to use by considering the projected human dietary exposure to the color additive, the additive's toxicological data, and other relevant information, such as published literature,' the agency stated in a news release.
The embrace of natural dyes is due to health concerns around artificial colorants, such as increased risk of cancer and neurobehavioral issues. While some manufacturers acknowledge these concerns, they have also highlighted the challenges involved in an industrywide shift to alternative dyes, which is likely due to both state-level bans and the FDA's requirement that food companies remove red dye No. 3 — banned in January — from foods by January 15, 2027.
'Natural colors can be more expensive from a cost-in-use perspective depending on the raw ingredient being used,' Amy Agallar, vice president of investor relations and treasurer at Sensient, said via email May 2. 'The raw ingredients can vary due to many factors such as availability, time to harvest and color availability from the raw material. The natural color needed to replace a synthetic color can be ten times that of a synthetic product.'
That discrepancy is partly due to some food and beverage products requiring heat processing or acids that affect the stability of natural colors, Agallar added. 'Some natural colors are also not very light stable and this may be needed in the end application.'
Additionally, 'studies show that customers prefer products with color and are more likely to purchase food and beverages with a color that matches the expected flavor,' Agallar said. 'Consumers use the color to identify how a product will taste. Food manufacturers currently use natural color products in about 80% of new colored food and beverages released in the US each year.'
There's little funding for research on artificial food dyes, and even less for the study of emerging alternatives — so it's not yet known whether these new natural dyes could have any effect on human health. But with most natural dyes coming from plants and being used in small quantities, 'it's hard to believe they'd have any effect' on the general population, Dr. Marion Nestle, Paulette Goddard Professor of Nutrition, Food Studies, and Public Health, Emerita, at New York University, told CNN in a previous story.
Sensient has developed its own safety program, Certasure, Agallar said. 'This program ensures that our natural colors are free of pesticides, heavy metals, microbiological contamination, adulteration, and unauthorized solvents.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
33 minutes ago
- CBS News
Cook County jury awards $20.5 million to family of girl who died from toxic levels of morphine
A Cook County jury awarded more than $20 million in damages to the family of an 11-year-old girl who died from toxic levels of morphine. In October 2020, Ava Wilson was recovering from leukemia when she went for a follow-up appointment at Advocate Children's Hospital. During her appointment, she was crying from pain, and had difficulty walking, according to her family's attorneys. Lab tests revealed she had low platelet counts, low blood cell counts, high liver enzymes, and low blood pressure. She was discharged from Advocate Children's Hospital with instructions to take 15 milligrams of morphine every four hours, triple the amount of her previous prescriptions. A nurse practitioner also increased her gabapentin prescription. Approximately 36 hours after getting home, she died in her sleep from acute drug toxicity of several substances, including lethal levels of morphine in her system at the time of her death. Her family's attorneys said the hospital should have admitted Ava to the hospital to get her blood pressure under control and treat the cause of her pain, but simply sent her home with excessive pain medications. "Ava's body was yelling out to these clinicians, 'help me!', and they just ignored it," attorney Matthew Williams said. After a civil trial, a jury awarded her family $20.5 million in damages. "While nothing will ease the depth of Ava's loved ones' pain, the family appreciates that the jury recognized that Ava's death was preventable and that she should still be with them today," attorney Aaron Boeder said.


Newsweek
34 minutes ago
- Newsweek
Mushroom Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hofood99 Inc. is recalling packages of their Enoki Mushrooms due to fears the product may be contaminated with listeria. Newsweek reached out to the company via phone for additional comment on Wednesday and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that Listeria monocytogenes is an organism that could cause serious and sometimes fatal infections in frail or older people, young children and those with weakened immune systems. Listeria could also lead to stillbirths or miscarriages in pregnant women, the FDA says. What To Know According to the FDA alert, the mushrooms were distributed nationwide to stores and retailers. The recalled mushrooms are sold in 200-gram green plastic packaging with a with UPC Barcode of 6 976532 310051 seen on the back label. No illnesses or injuries have been reported related to the recalled mushrooms. The mushrooms were distributed by Hofood99 Inc., located at 21903 56th Avenue Oakland Gardens, New York 11364. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) What People Are Saying The FDA in the alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled mushrooms may return the product to the original place of purchase for a full refund or destroy it, the FDA says. People with additional questions may contact the company at (917) 756-9833 weekdays from 9 a.m. to 2 p.m.


Medscape
35 minutes ago
- Medscape
Fast Five Quiz: Late-Onset Pompe Disease
Multiple genetic variants have been associated with LOPD. However, the c.-32-13T>G splice site variant is found in up to 90% of adults and 50% of pediatric patients. Patients with LOPD often have compound heterozygous genotypes, with one allele carrying the common c.-32-13T>G splice-site variant and the other harboring a more deleterious GAA mutation (eg, nonsense, frameshift, or large deletion). Other variants— such as and c.1935C>A — are more commonly seen in infantile forms of Pompe disease. Learn more about the pathophysiology of LOPD. Diagnosis of LOPD typically follows a two-step approach: first, measuring GAA enzyme activity (often via dried blood spot assay) followed by confirmatory molecular genetic testing to identify pathogenic GAA variants. Although once considered a first-line diagnostic tool for LOPD, muscle biopsy is no longer preferred due to its invasive nature and the non-specificity of histologic findings. Muscle biopsy may still be considered in rare, ambiguous cases when enzyme and genetic testing are inconclusive or conflicting. CK levels might be elevated in some patients but are nonspecific and primarily serve to raise clinical suspicion. Learn more about the workup for LOPD. Enzyme replacement therapy (ERT) has significantly changed the natural history of the disease by improving survival and stabilizing motor and respiratory function. However, key limitations in skeletal muscle uptake and variability in clinical response remain. This is due to low expression of the mannose-6-phosphate receptor in muscle tissue, which hampers enzyme internalization. As a result, patients might experience a limited or plateaued response. Newer approaches, including modified ERT and gene therapy, are being developed to address this issue. High toxicity to cardiac muscle, uniform patient response, and development of cardiac hypertrophy have not been reported as key limitations. Learn more about treatment options for LOPD. NBS programs have reshaped the understanding of Pompe disease, particularly LOPD. A significant proportion of screen-positive newborns harbor genetic variants associated with LOPD, including pseudo deficiency alleles and variants of uncertain significance. These individuals are often asymptomatic at birth and might not develop symptoms for years, if at all. This has raised important clinical questions around monitoring, counseling, and when (or whether) to initiate therapy; expanded screening has also revealed that the true prevalence of LOPD might be higher than historical estimates suggested. Learn more about the management of LOPD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: UCSF/Science Source